Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer (ICAR)

STATUS

Recruiting
End date

Nov 30, 2024
participants needed

30
sponsor

Centre Antoine Lacassagne

Updated on 25 March 2022

See if I qualify

etoposide

cancer chemotherapy

neuroendocrine tumor

Summary

The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy in localized small cell lung cancer due to:

The over-expression of carbonic anhydrases in this type of cancer,
The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines,
The observed synergy between irradiation and inhibition of carbonic anhydrases,
Potential anti-tumor immune effect caused by decreased extracellular acidity.

Description

Compared with healthy cells, glucose metabolism is greatly modified in cancer cells because of their highly proliferative character. This differential tumor / healthy tissue property is an opportunity to be able to propose a treatment whose therapeutic gain can be major (targeted treatment). Preclinical studies are multiple and showed that the targeting of overexpressed proteins (carbonic anhydrases) and involved in glycolytic metabolism can lead to a significant anti-tumor effect. This has never been tested in humans.

Acetazolamide is a molecule commonly used for non carcinologic purposes but has demonstrated anti-tumor activity in preclinical studies; there is also synergy radiotherapy / targeting of carbonic anhydrases. Therefore, the investigators propose to study the combination of acetazolamide / radiotherapy / chemotherapy with platinum and etoposide in localized Small Cell Lung cancer.

This would be the first study:

targeting glucose metabolism,
testing the effectiveness of acetazolamide in oncology,
testing the synergy radiotherapy / targeting glycolytic metabolism,
trying to manipulate the anti-tumor immune system indirectly, by decreasing extracellular acidosis.

Details

Condition	Small Cell Lung Cancer
Treatment	acetazolamide in combination with platinum and etoposide-based radiochemotherapy
Clinical Study Identifier	NCT03467360
Sponsor	Centre Antoine Lacassagne
Last Modified on	25 March 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Age > or = 18 years
	Performance Status 0 to 2
	Patient with an histologically non-metastatic localized Small cell lung cancer
	Patient who must start radiotherapy treatment combined with chemotherapy with platinum and etoposide, Note: The decision of the Multidisciplinary Consultation Team must be notified in the patient's medical file
	Evaluation lesion according to the criteria RECIST 1.1 and / or according to the criteria PERCIST 1.0
	Women of childbearing potential must have a negative serum pregnancy test within 72 hours of the first administration of the study treatment
	If the patient is a woman of childbearing potential, she must be surgically sterile or agree to use two adequate methods of contraception throughout the duration of the study until 1 month after the last administration of the study treatment. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year, Note: Abstinence is acceptable if it is the patient's usual and preferred form of contraception
	If the male patient has one or more female partners of childbearing age, he / she must agree to use an adequate method of contraception, starting at the first administration of the study treatment up to 1 month after the last administration of the treatment. of the study, Note: Abstinence is acceptable if it is the patient's usual and preferred form of contraception
	Patient willing and able to provide written informed consent/assent for the trial
	Patient affiliated with a health insurance system
Exclusion Criteria
	Patient with metastatic disease
	History of thoracic irradiation or near / in the thoracic irradiation field
	Patient who refuses to participate in the study or unable to agree
	Contraindication to thoracic radiotherapy treatment: congestive heart failure unbalanced (ejection fraction <30%, clinical signs), severe respiratory failure
	COPD grade IV according to the GOLD classification
	Some GOLD III COPD and any patient with a respiratory defect defined as: oxygen dependence and / or FEV1 <40% normal and / or, DLCO <40% predictive value and / or vital capacity <40% predictive value
	Contraindication to acetazolamide: hypersensitivity to acetazolamide, severe hepatic
	Patient currently receiving one or more treatments described in section 6.9 of the protocol
	renal or adrenal insufficiency, sulfonamide intolerance, history of renal
	History of cancer, with the exception of cancers in complete remission for more than 5 years, completely resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer
	colic, allergy to wheat other than celiac disease
	People particularly vulnerable as defined in Articles L.1121-5 to -8 of the French Healthcare Code, including: person deprived of freedom by an administrative or judicial decision, adult being the object of a legal protection measure or outside a state to express their consent, pregnant or breastfeeding women

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

etoposide

cancer chemotherapy

neuroendocrine tumor

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer (ICAR)